News
Events
LumiraDx Announces New Investment for Ongoing Development of its Point of Care Molecular Tuberculosis Test
2022/12/15
LumiraDx Receives CTDA Approval for its LumiraDx Dual-Target SARS-CoV-2 STAR Complete
Point of Care (POC) Survey Reveals Majority of U.K. Clinicians Endorse Climate Benefits of POC Through Reduction of Carbon Emissions and Anticipate Future Growth of POC Testing to Come from Community Settings
2022/12/08
LumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c Test
2022/11/14
LumiraDx Reports Third Quarter 2022 Results
2022/11/09
LumiraDx to Announce Third Quarter Financial Results and Host Quarterly Conference Call on November 9
2022/11/02
LumiraDx named by Frost & Sullivan as the 2022 Europe Technology Innovation Leader in the Microfluidics Point of Care Diagnostics Industry
2022/10/12
LumiraDx Partners with British In Vitro Diagnostics Association to Report on the Role of Rapid Diagnostics in Tackling Antimicrobial Resistance
2022/09/22
Medical Product Outsourcing: Integrating Point of Care to Future Proof our Community Health System
2022/09/16
LumiraDx Awarded Rapid Testing Agreement with Premier, Inc.
2022/09/08
KevinMD: Immediate, accurate diagnosis is crucial to the future of equitable patient care
2022/08/29
Health Tech World: LumiraDx COVID-19 antigen test alone in exceeding WHO target in Cochrane Review
2022/08/25
Health Europa: LumiraDx’s COVID-19 antigen test is the only test exceeding WHO’s desirable sensitivity target
LumiraDx Reports Second Quarter 2022 Results
2022/08/18
LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 18 2022
2022/08/12
LumiraDx to Present on Impact of its Next-Generation Microfluidic Technology at American Association for Clinical Chemistry (AACC) Annual Conference in Chicago
2022/07/25
LumiraDx Announces Pricing of Public Offering of Common Shares and Concurrent Private Placement
2022/07/21
LumiraDx Announces Proposed Public Offering of Common Shares
2022/07/19
London Loves Business: Groundbreaking Covid test gives lifeline to businesses as cases soar
2022/06/30
HealthTech World: The versatile diagnostic platform that passes the test
2022/06/14
LumiraDx Achieves CE Mark for COVID-19 Antigen Test on Amira, its New Low-Cost Testing System
2022/06/09
LumiraDx Receives CE Mark for Two Multiplex Tests: LumiraDx Dual-Target SARS-CoV-2 STAR Complete and LumiraDx SARS-CoV-2 & Flu A/B RNA STAR Complete
2022/06/08
LumiraDx Expands its Cardiovascular Testing Portfolio with CE Marking of its NT-proBNP Test and new Exclusion Claim for its D-Dimer Test
2022/06/02
360Dx: LumiraDx Gets New, Expanded CE Marks for Point-of-Care Cardiovascular Disease Tests
LumiraDx HbA1c Test Achieves CE Mark, Addresses Growing Global Need for Diabetes Screening and Monitoring with its Next-Generation Point of Care Diagnostic Platform
2022/05/26
Medical Device Network: LumiraDx’s HbA1c test receives CE mark for diabetes screening
HealthTech World: LumiraDx receives WHO Emergency Use Listing for SARS-CoV-2 Ag Test
MD+DI: LumiraDx Scores CE Mark for Fast POC COVID-19 Test
2022/05/24
LumiraDx Receives WHO Emergency Use Listing for SARS-CoV-2 Ag Test
2022/05/20
LumiraDx Five-Minute SARS-CoV-2 Ag Ultra Test Achieves CE Marking
2022/05/19
HealthTech World: Antimicrobial resistance: New guidance on using CRP tests in primary care to reduce antibiotic overprescribing
2022/05/18
LumiraDx Reports First Quarter 2022 Results
2022/05/11
Bill Gates Ted Talk: We Can Make COVID-19 the Last Pandemic | Bill Gates | TED
2022/04/29
Health Europa: Answering healthcare needs with point-of-care testing
2022/04/26
Forbes: Could The Innovation Stack Revolutionize Your Industry?
2022/04/15
Fast Company: Bill Gates wants to create a global pandemic first response team
2022/04/12
LumiraDx Reports Fourth Quarter and Full Year 2021 Results
2022/03/10
LumiraDx Announces Pricing of $56.5 Million Convertible Notes Offering
2022/03/01
LumiraDx Receives UK MHRA Approval for SARS-CoV-2 RNA STAR Complete
2022/02/21
Health Europa: LumiraDx: Fighting antimicrobial resistance with innovative POC testing
2022/01/26
LumiraDx Lab Analysis Confirms its COVID-19 Antigen Test Detects the Omicron Variant
2022/01/14
LumiraDx CRP Test Achieves CE Marking
2022/01/11
LumiraDx has Commenced Shipments in Europe for its COVID-19 & Flu A/B MicrofluidicAntigen Test
LumiraDx COVID-19 & Flu A/B Rapid Antigen Test Achieves CE Marking
2021/12/23
LumiraDx Fast Lab Solutions Partners with Audere for At-Home Self- Collection Solution for use with SARS-CoV-2 RNA STAR Complete
2021/12/15
FDA Reissues LumiraDx Fast Lab Solutions’ EUA for SARS CoV-2 RNA STAR Complete Molecular Reagents to Allow High Throughput and Asymptomatic Testing Solutions
2021/12/01
LumiraDx Monitoring of New and Emerging Variants of Concern and Detection of the Omicron Variant
2021/11/29
LumiraDx Reports Third Quarter 2021 Financial Results
2021/11/10
LumiraDx to Announce Third Quarter 2021 Financial Results and Host Quarterly Conference Call on November 10
2021/11/02
LumiraDx receives approval for its COVID-19 Antigen Test for use in India
2021/10/20
LumiraDx Announces FDA EUA Submission for its SARS-CoV-2 & Flu A/B Rapid Antigen Test
2021/10/15
360Dx: Post-IPO, LumiraDx Pushes Adoption of POC Instrument, Eyes Test Menu Expansion
2021/10/07
360Dx: Point-of-Care Test Developer LumiraDx Goes Public on Nasdaq
2021/09/29
LumiraDx to Become Publicly Traded following Successful Closing of Merger with CA Healthcare Acquisition Corp.
2021/09/28
Bill & Melinda Gates Foundation’s Goalkeepers report features LumiraDx’s work in the fight against COVID-19
2021/09/21
LumiraDx and CA Healthcare Acquisition Corp Revise Transaction Terms, Expanded Strategic Roadmap for Next-Generation Point-of-Care Diagnostics
2021/08/20
PLOS Medicine publishes systematic review and meta-analysis of more than 60 SARS- CoV-2 antigen tests: Ranks LumiraDx’s SARS-CoV-2 Ag Test as most sensitive and accurate
2021/08/18
LumiraDx Receives FDA Emergency Use Authorization for its COVID-19 Antibody Test, Now Allowing COVID-19 Antigen and Antibody Testing on a Single Point of Care Platform
2021/08/05
LumiraDx at ECCMID 2021: Performance Data presented on the use of the LumiraDx Platform with LumiraDx SARS-CoV-2 Ag and Ab Test
2021/07/09
LumiraDx Achieves CE Mark for Its High Sensitivity, High Throughput COVID-19 Molecular Test, RNA STAR Complete
2021/07/02
LumiraDx High Sensitivity Point of Care Antigen Test Detects Against Leading Variants of Concern including Alpha, Beta, Gamma, and Delta
2021/06/24
LumiraDx Announces Commercial Launch of its SARS-CoV-2 Ag Pool Test in CE Mark countries
2021/06/17
Shionogi Announces Agreement of Joint Sales with LumiraDx Japan for Novel Coronavirus Antigen test agent and diagnostic instrument in Japan
2021/04/21
LumiraDx Receives Reissued FDA Emergency Use Authorization for Its High Sensitivity, Rapid COVID-19 Molecular Lab Test
2021/04/13
LumiraDx, a Next-Generation Point of Care Diagnostics Testing Company to List on Nasdaq via Merger with CA Healthcare Acquisition Corp
2021/04/07
Bloomberg: Test Maker LumiraDx to Go Public in $5 Billion SPAC Deal
2021/04/06
LumiraDx Receives SARS-CoV-2 Antigen Test Authorization in Japan and Brazil; Italy Recommends Expansion of Microfluidic Antigen Testing
2021/01/21
SKUP Reports Positive Evaluation of the LumiraDx SARS-CoV-2 Antigen Test in Symptomatic and Asymptomatic Patients
2021/01/13
LumiraDx Receives Authorization by Switzerland´s Federal Office of Public Health
2020/12/21
Global Partnership to Introduce a Connected, Point of Care Diagnostic Platform for COVID-19 Antigen Testing in Africa
2020/11/10
LumiraDx COVID-19 Antigen Test Achieves CE Mark
2020/08/31
LumiraDx Receives FDA Emergency Use Authorization for Point of Care COVID-19 Antigen Test
2020/08/20
LumiraDx Launches first-of-its-kind smart Diagnostic platform
2019/08/29
Supporting healthier lives, for individuals, communities and wider society.
Enabling responsive, personal relationships between patients and care teams.
Controlling and reducing costs to help ease pressure on healthcare budgets.